Navigation Links
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Date:8/22/2008

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"There is an urgent medical need for effective treatment options for non- small cell lung cancer because current treatment strategies have only a minimal impact on survival," said Joachim von Pawel, M.D., a principal investigator in the study from the Asklepios Fachkliniken Munchen-Gauting, Germany. "The majority of patients who are newly diagnosed with non-small cell lung cancer have locally advanced or metastatic disease that is currently incurable. We look forward to evaluating the potential of mapatumumab plus chemotherapy to offer a new approach to the first-line treatment of this deadly disease."

The NSCLC trial is a randomized, multi-center, open-label Phase 2 study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the treatment of advanced non-small cell lung cancer (Stage IIIB or IV). 111 patients have been randomly assigned to one of three treatment groups and treated with either the two-agent combination of carboplatin and paclitaxel or the three-agent combination of carboplatin, paclitaxel, and HGS-ETR1 at either 10 mg/kg or 30 mg/kg. HGS announced the initiation of the NSCLC trial In December 2007.

"A growing body of precl
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
2. ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. ProteoTechs Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimers Disease
5. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
6. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
7. New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans
8. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
11. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... 2014  A $3 million grant from The Glenn ... Michigan to establish a national center of excellence in ... Aging Research at U-M will focus on exploiting and ... effects of aging and postpone diseases in animal models. ... help develop medications that may help people live longer, ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, 2014 ... the National Hemophilia Foundation,s (NHF) new three-year initiative, ... to people with hemophilia and their families/caregivers to ... can impede disease management. The curriculum for the ... Your Provider About Pain , focuses on improving ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... TARRYTOWN, N.Y., Nov. 2, 2011 Siemens Healthcare Diagnostics ... a partnership aimed at setting new standards in ... of patients, infectious disease states and potential treatment paths. ... make existing Siemens molecular HIV tests compatible with the recently ...
... world leader in diabetes care, announced today that it has ... (DHF), a non-profit organization that raises diabetes awareness and connects ... of the Drive the Switch program, which has motivated more ... and their doctor about options for insulin delivery, like the ...
Cached Medicine Technology:New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 2New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 2Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 4Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 5Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 6Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 7
(Date:9/18/2014)... ORLANDO, Fla., and DENVER (PRWEB) September 18, 2014 ... office in Orlando. This new office, managed by Todd ... provide health systems in the southeast with the benefits ... without sacrificing the knowledge and advantage of local project ... regional offices, NexCore has expanded its presence across the ...
(Date:9/18/2014)... September 18, 2014 Once again, Hickman’s ... breakfast restaurants around the Valley to celebrate PJs & ... “World Egg Day”: Friday, October 10, 2014. The “breakfast ... locations to benefit Arizona’s Children Association (AzCA) foster care ... dinner at each participating restaurant on October 10 are ...
(Date:9/18/2014)... are trying to learn more about a condition called ... young athletes. In people with sickle cell trait, ... breakdown that can lead to kidney damage and cardiac ... in the United States collapsed and died during training ... "More student-athletes with sickle cell trait have died ...
(Date:9/18/2014)... decades, researchers have tried to develop broadly effective vaccines ... malaria, and tuberculosis. While limited progress has been made ... available that can protect most people from these devastating ... when vaccines just aren,t working? , At Caltech, Nobel ... problem in a different way. Whereas vaccines introduce substances ...
(Date:9/18/2014)... to support private efforts to provide mental health services ... for similar efforts should federal officials decide to expand ... the VA health system, according to a new RAND ... joint project of philanthropic groups and major academic medical ... and other services to veterans and their families. , ...
Breaking Medicine News(10 mins):Health News:NexCore Group Opens Regional Office in Orlando, Florida 2Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2Health News:Scientists Studying Sickle Cell Trait 2Health News:A new way to prevent the spread of devastating diseases 2Health News:A new way to prevent the spread of devastating diseases 3Health News:A new way to prevent the spread of devastating diseases 4Health News:A new way to prevent the spread of devastating diseases 5Health News:Study provides insight about providing private mental health service to veterans 2Health News:Study provides insight about providing private mental health service to veterans 3
... the U.S., demonstrated both the efficacy and ... with nasal symptoms associated with perennial allergic ... today the U.S. Food and Drug Administration (FDA) ... children aged 2-5,years old for the treatment of ...
... unclear, experts say , , MONDAY, Sept. 22 (HealthDay News) ... to take much longer to get to the hospital when ... new study finds. , The finding suggests that patients without ... critical window for time-sensitive care following a heart attack, the ...
... Cyberonics, Inc. (Nasdaq:,CYBX) today announced that its corporate ... The facility incurred no damage from the ... resulting in the Company operating from its,disaster recovery ... returned to normal, including all shipments and production ...
... experience trouble, study finds , , MONDAY, Sept. 22 (HealthDay ... -- which include Crestor, Lipitor, Pravachol and Zocor -- ... Canadian study indicates. , Delirium is a common, and ... of surgery, according to study lead author Dr. Donald ...
... previously unknown mechanism of immunity suggests that there may ... adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at ... (HSPH). The findings, published in the open-access journal ... development of novel pneumococcal vaccines. (The current vaccine, Prevnar, ...
... Pa., Sept. 22 A group of southeastern,Pennsylvania ... on,Thursday, September 25 at 12:00 PM at their ... maternity care crisis in Pennsylvania, and how a,legislative ... State,Representative Mike Vereb (R-Montgomery) and other legislators from,southeastern ...
Cached Medicine News:Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 2Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 3Health News:FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old 4Health News:Heart Attack Care Often Delayed for the Poor 2Health News:Heart Attack Care Often Delayed for the Poor 3Health News:Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike 2Health News:Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike 3Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 2Health News:Cholesterol Drugs May Raise Post-Op Delirium Risk 3Health News:New insights could lead to a better pneumococcal vaccine 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: